COMMERCIAL RIGHTS AND BROADEN CLINICAL INDICATIONS
http://www.mesoblast.com/newsroom/asx-announcements
Major Points
- New composition of matter patent claims granted in United States
- New patents broaden Mesoblast’s commercial development strategy, including new products for neural regeneration, dental applications, and cosmetic surgery
- Mesoblast continues to strengthen exclusive commercial ownership of proprietary stem cell platform
Melbourne, Australia; 24 May 2011: Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company?s product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
Together with earlier composition of matter claims in US patent 7,122,178 relating to Mesoblast?s proprietary Mesenchymal Precursor Cell (MPCs) technology platform, these new US patents 7,052,907 and 7,947,266 give Mesoblast exclusive ownership over MPCs derived from a variety of sources, including dental pulp and adipose tissue (fat), in addition to bone marrow.
The MPCs derived from dental pulp may be particularly effective for the treatment and prevention of neural degenerative diseases such as Parkinson's disease and Alzheimer?s disease, as well as for dental applications such as regenerating teeth. Adipose-derived MPCs may have particular benefits for reconstructive surgery and cosmetic indications.
The new granted US patents extend Mesoblast?s ownership of MPCs through to 2025, and ensure that during this period only Mesoblast can commercialize MPC products in the United States, the world?s largest healthcare market.
Beyond that period, under the United States Patient Protection and Affordable Care Act enacted in 2010, Mesoblast may be entitled to further exclusive commercial protection for the company?s biologic products in the United States.
Mesoblast Chief Executive, Professor Silviu Itescu, said the new patents are major assets that confer certainty, broaden the range of product offerings by the company, and significantly increase the commercial value of the platform technology.
“Maintaining commercial exclusivity for our adult stem cell products through a robust international patent portfolio is fundamental to our commercial strategy,” Professor Itescu added.
About Mesoblast Limited
Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) is a world leader in the development, manufacture, and commercialization of biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights to a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). More information - www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications Director
T: + 61 (0) 3 9639 6036
E: julie.meldrum@mesoblast.com
Recent MESO News
- FDA Commentary Sends Biotech Soaring During Premarket Hours • AllPennyStocks.com • 03/26/2024 01:25:00 PM
- United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 03/26/2024 02:34:20 AM
- Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer • GlobeNewswire Inc. • 03/13/2024 11:30:47 PM
- United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) • GlobeNewswire Inc. • 03/10/2024 11:54:12 PM
- Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/28/2024 10:57:09 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 02/15/2024 12:46:40 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 02:34:30 AM
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 • GlobeNewswire Inc. • 01/31/2024 02:13:34 AM
- Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment • Dow Jones News • 01/19/2024 12:28:00 AM
- United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 01/18/2024 11:36:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 11:33:54 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 01/05/2024 02:57:09 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 12/22/2023 10:13:02 PM
- Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease • GlobeNewswire Inc. • 11/26/2023 11:56:21 PM
- Biotech Shares Soar Following Major Announcement • AllPennyStocks.com • 11/22/2023 06:35:00 PM
- Biotech Shares Soar Following Major Announcement • AllPennyStocks.com • 11/22/2023 06:35:00 PM
- Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD • GlobeNewswire Inc. • 11/21/2023 11:32:27 PM
- Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 10/31/2023 12:04:17 AM
- Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee • GlobeNewswire Inc. • 09/26/2023 10:18:49 AM
- Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval • GlobeNewswire Inc. • 09/21/2023 07:30:42 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 09/06/2023 10:42:49 AM
- Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023 • GlobeNewswire Inc. • 08/30/2023 11:07:02 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 08/29/2023 11:00:00 AM
- Mesoblast ADSs Plunge Premarket on Latest FDA Rejection • Dow Jones News • 08/04/2023 01:03:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM